Bristol-myers Squibb Compnay

Bristol-myers Company

Robert J Behme

Joseph A Scott

Robert L Alexander

Terry T Kensler

Dana Brooke

Douglas G Mikolasek

The hemi-hydrate form of the cerebral function enhancing agent 1-[[1-[2-(trifluoromethyl)-4-pyrimidinyl]-4-piperidinyl]-methyl-2-pyrrolid inone, or BMY-21502 as it is more commonly designated, is an improved form of drug substance having equivalent biopharmaceutical properties compared to the known anhydrous form but providing cost, safety and ecological advantages in manufacture over the known anhydrous form.

Useful hemi-hydrate form of a cerebral function enhancing agent

Improved lyophilizate compositions of ifosfamide comprising urea as the primary excipient and, optionally, mesna, are produced in a modified freeze-drying process to give products with increased heat stability and extended shelf storage life.

Lyophilized ifosfamide compositions

A process for conversion of one polymorphic crystalline form of buspirone into its other polymorphic crystalline form.

Growing community of inventors

Newburgh, IN, United States of America

Robert J Behme